Company La Jolla Pharmaceutical Company OTC Bulletin Board
Equities
US5034596040
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | La Jolla Pharmaceutical Announces Management Changes | CI |
2022 | La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from NASDAQ Composite Index | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 61 | 20-05-31 |
Tony Hodges
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-11 |
Luke Seikkula
COO | Chief Operating Officer | 60 | 18-12-31 |
Paula Rusu
PRN | Corporate Officer/Principal | - | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Marianne Zhen
BRD | Director/Board Member | 55 | 22-08-21 |
Pavel Raifeld
BRD | Director/Board Member | 40 | 22-08-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 24,936,883 | 24,826,697 ( 99.56 %) | 0 | 99.54 % |
Stock B | 0 | 3,907 | 0 | 0 |
Company contact information
La Jolla Pharmaceutical Co.
201 Jones Road Suite 400
02451, Waltham
+617 715 3600
https://www.lajollapharmaceutical.comSector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- LJPC Stock
- Stock
- Company La Jolla Pharmaceutical Company